India Thalassemia Market Research Report Information by Type (Alpha-thalassemia and Beta-thalassemia) and by Treatment & Diagnosis (Treatment [Blood Transfusions, Drugs, Folic Acid Supplements] and Diagnosis [Instruments and Reagents) - Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TECHNIQUE

3.8 DATA MODELLING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELLING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 GROWING GOVERNMENT INITIATIVES AND SUPPORT TO RAISE AWARENESS FOR THALASSEMIA

4.2.2 INCREASED PREVALENCE OF THALASSEMIA IN INDIA

4.3 RESTRAINTS

4.3.1 SIDE EFFECTS ASSOCIATED WITH THALASSEMIA DRUG TREATMENT

4.4 OPPORTUNITY

4.4.1 LAUNCH OF SERVICES WITH ADVANCEMENTS IN PRENATAL AND NEWBORN SCREENING TECHNOLOGIES

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 THREAT OF NEW ENTRANTS

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 THREAT OF SUBSTITUTES

5.1.4 BARGAINING POWER OF BUYERS

5.1.5 INTENSITY OF RIVALRY

5.2 IMPACT OF COVID-19 ON THE INDIA THALASSEMIA MARKET

6 INDIA THALASSEMIA MARKET, BY TYPE

6.1 INTRODUCTION

6.1.1 ALPHA-THALASSEMIA

6.1.2 BETA-THALASSEMIA

7 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS

7.1 INTRODUCTION

7.2 TREATMENT

7.2.1 BLOOD TRANSFUSIONS

7.2.2 DRUGS

7.2.3 FOLIC ACID SUPPLEMENTS

7.3 DIAGNOSIS

7.3.1 INSTRUMENTS

7.3.2 REAGENTS

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION

8.2 MARKET SHARE ANALYSIS, 2022

8.3 COMPETITOR DASHBOARD

8.4 PUBLIC PLAYERS STOCK SUMMARY

8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

8.6.1 PRODUCT LAUNCH

9 COMPANY PROFILES

9.1 CADILA PHARMACEUTICALS

9.1.1 COMPANY OVERVIEW

9.1.2 FINANCIAL OVERVIEW

9.1.3 PRODUCTS OFFERED

9.1.4 KEY DEVELOPMENTS

9.1.5 SWOT ANALYSIS

9.1.6 KEY STRATEGIES

9.2 AGIOS PHARMACEUTICALS, INC

9.2.1 COMPANY OVERVIEW

9.2.2 FINANCIAL OVERVIEW

9.2.3 PRODUCTS OFFERED

9.2.4 KEY DEVELOPMENTS

9.2.5 KEY STRATEGIES

9.3 CIPLA INC

9.3.1 COMPANY OVERVIEW

9.3.2 FINANCIAL OVERVIEW

9.3.3 PRODUCTS OFFERED

9.3.4 KEY DEVELOPMENTS

9.3.5 KEY STRATEGIES

9.4 NOVARTIS AG

9.4.1 COMPANY OVERVIEW

9.4.2 FINANCIAL OVERVIEW

9.4.3 PRODUCTS OFFERED

9.4.4 KEY DEVELOPMENTS

9.4.5 SWOT ANALYSIS

9.4.6 KEY STRATEGIES

9.5 CENTURION REMEDIES PRIVATE LIMITED

9.5.1 COMPANY OVERVIEW

9.5.2 FINANCIAL OVERVIEW

9.5.3 PRODUCTS OFFERED

9.5.4 KEY DEVELOPMENTS

9.5.5 KEY STRATEGIES

9.6 HEALING PHARMA INDIA PVT. LTD.

9.6.1 COMPANY OVERVIEW

9.6.2 FINANCIAL OVERVIEW

9.6.3 PRODUCTS OFFERED

9.6.4 KEY DEVELOPMENTS

9.6.5 KEY STRATEGIES

9.7 REWINE PHARMACEUTICAL

9.7.1 COMPANY OVERVIEW

9.7.2 FINANCIAL OVERVIEW

9.7.3 PRODUCTS OFFERED

9.7.4 KEY DEVELOPMENTS

9.7.5 KEY STRATEGIES

9.8 SUN PHARMACEUTICAL INDUSTRIES LTD.

9.8.1 COMPANY OVERVIEW

9.8.2 FINANCIAL OVERVIEW

9.8.3 PRODUCTS OFFERED

9.8.4 KEY DEVELOPMENTS

9.8.5 SWOT ANALYSIS

9.8.6 KEY STRATEGIES

9.9 BRISTOL-MYERS SQUIBB COMPANY

9.9.1 COMPANY OVERVIEW

9.9.2 FINANCIAL OVERVIEW

9.9.3 PRODUCTS OFFERED

9.9.4 KEY DEVELOPMENTS

9.9.5 SWOT ANALYSIS

9.9.6 KEY STRATEGIES

9.10 TREXGEN PHARMACEUTICALS PVT. LTD.

9.10.1 COMPANY OVERVIEW

9.10.2 FINANCIAL OVERVIEW

9.10.3 PRODUCTS OFFERED

9.10.4 KEY DEVELOPMENTS

9.10.5 KEY STRATEGIES

10 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT

TABLE 2 INDIA THALASSEMIA MARKET, BY TYPE, 2019–2032 (USD BILLION)

TABLE 3 INDIA THALASSEMIA MARKET, BY TREATMENT & DIAGNOSIS, 2019–2032 (USD BILLION)

TABLE 4 INDIA THALASSEMIA MARKET, FOR TREATMENT, BY TYPE 2019–2032 (USD BILLION)

TABLE 5 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019–2032 (USD BILLION)

TABLE 6 INDIA THALASSEMIA MARKET, FOR DIAGNOSIS, BY TYPE 2019–2032 (VOLUME UNITS)

TABLE 7 INDIA THALASSEMIA MARKET, FOR INSTRUMENTS, BY TYPE 2019–2032 (VOLUME UNITS)

TABLE 8 INDIA THALASSEMIA MARKET, FOR REAGENTS, BY TYPE 2019–2032 (VOLUME UNITS)

TABLE 9 PUBLIC PLAYERS STOCK SUMMARY

TABLE 10 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 11 PRODUCT LAUNCH

TABLE 12 CADILA PHARMACEUTICALS: PRODUCT OFFERED

TABLE 13 AGIOS PHARMACEUTICALS, INC: PRODUCT OFFERED

TABLE 14 AGIOS PHARMACEUTICALS, INC: KEY DEVELOPMENTS

TABLE 15 CIPLA INC: PRODUCT OFFERED

TABLE 16 NOVARTIS AG: PRODUCTS OFFERED

TABLE 17 CENTURION REMEDIES PRIVATE LIMITED: PRODUCTS OFFERED

TABLE 18 HEALING PHARMA INDIA PVT. LTD.: PRODUCTS OFFERED

TABLE 19 REWINE PHARMACEUTICAL: PRODUCTS OFFERED

TABLE 20 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW

TABLE 21 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 22 BRISTOL-MYERS SQUIBB COMPANY: PRODCUTS OFFERED

TABLE 23 TREXGEN PHARMACEUTICALS PVT. LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 INDIA THALASSEMIA MARKET: STRUCTURE

FIGURE 2 INDIA THALASSEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: INDIA THALASSEMIA MARKET

FIGURE 6 INDIA THALASSEMIA MARKET; TYPE SEGMENT ATTRACTIVENESS, (USD BILLION)

FIGURE 7 INDIA THALASSEMIA MARKET, BY TYPE, 2022 & 2032 (USD BILLION)

FIGURE 8 INDIA THALASSEMIA MARKET SHARE (%), BY TYPE, 2022

FIGURE 9 INDIA THALASSEMIA MARKET; TREATMENT SEGMENT ATTRACTIVENESS, (USD BILLION)

FIGURE 10 INDIA THALASSEMIA MARKET, BY TREATMENT, 2022 & 2032 (USD BILLION)

FIGURE 11 INDIA THALASSEMIA MARKET SHARE (%), BY TREATMENT & DIAGNOSIS, 2022

FIGURE 12 INDIA THALASSEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022

FIGURE 13 COMPETITOR DASHBOARD: INDIA THALASSEMIA MARKET

FIGURE 14 CADILA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 CADILA PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 16 AGIOS PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 CIPLA INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 NOVARTIS AG: SWOT ANALYSIS

FIGURE 20 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 21 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW

FIGURE 22 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS